Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment

<p>Abstract</p> <p>Background</p> <p>Distinguishing new from recrudescent infections in post-treatment episodes of malaria is standard in anti-malarial drug efficacy trials. New infections are not considered malaria treatment failures and as a result, the prevention of...

Full description

Bibliographic Details
Main Authors: Shaukat Ayesha M, Gilliams Elizabeth A, Kenefic Leo J, Laurens Matthew B, Dzinjalamala Fraction K, Nyirenda Osward M, Thesing Phillip C, Jacob Christopher G, Molyneux Malcolm E, Taylor Terrie E, Plowe Christopher V, Laufer Miriam K
Format: Article
Language:English
Published: BMC 2012-06-01
Series:Malaria Journal
Subjects:
Online Access:http://www.malariajournal.com/content/11/1/207
id doaj-a1f81a1825624ad2ae95797ed1fb4355
record_format Article
spelling doaj-a1f81a1825624ad2ae95797ed1fb43552020-11-24T22:06:24ZengBMCMalaria Journal1475-28752012-06-0111120710.1186/1475-2875-11-207Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatmentShaukat Ayesha MGilliams Elizabeth AKenefic Leo JLaurens Matthew BDzinjalamala Fraction KNyirenda Osward MThesing Phillip CJacob Christopher GMolyneux Malcolm ETaylor Terrie EPlowe Christopher VLaufer Miriam K<p>Abstract</p> <p>Background</p> <p>Distinguishing new from recrudescent infections in post-treatment episodes of malaria is standard in anti-malarial drug efficacy trials. New infections are not considered malaria treatment failures and as a result, the prevention of subsequent episodes of malaria infection is not reported as a study outcome. However, in moderate and high transmission settings, new infections are common and the ability of a short-acting medication to cure an initial infection may be outweighed by its inability to prevent the next imminent infection. The clinical benefit of preventing new infections has never been compared to that of curing the initial infection.</p> <p>Methods</p> <p>Children enrolled in a sulphadoxine-pyrimethamine efficacy study in Blantyre, Malawi from 1998–2004 were prospectively evaluated. Six neutral microsatellites were used to classify new and recrudescent infections in children aged less than 10 years with recurrent malaria infections. Children from the study who did not experience recurrent parasitaemia comprised the baseline group. The odds of fever and anaemia, the rate of haemoglobin recovery and time to recurrence were compared among the groups.</p> <p>Results</p> <p>Fever and anemia were more common among children with parasitaemia compared to those who remained infection-free throughout the study period. When comparing recrudescent vs. new infections, the incidence of fever was not statistically different. However, children with recrudescent infections had a less robust haematological recovery and also experienced recurrence sooner than those whose infection was classified as new.</p> <p>Conclusions</p> <p>The results of this study confirm the paramount importance of providing curative treatment for all malaria infections. Although new and recrudescent infections caused febrile illnesses at a similar rate, recurrence due to recrudescent infection did have a worsened haemological outcome than recurrence due to new infections. Local decision-makers should take into account the results of genotyping to distinguish new from recrudescent infections when determining treatment policy on a population level. It is appropriate to weigh recrudescent malaria more heavily than new infection in assessing treatment efficacy.</p> http://www.malariajournal.com/content/11/1/207MalariaSulphadoxine-pyrimethamineDrug efficacyGenotypingRecrudescent infectionsNew infectionsMalawiAnaemia
collection DOAJ
language English
format Article
sources DOAJ
author Shaukat Ayesha M
Gilliams Elizabeth A
Kenefic Leo J
Laurens Matthew B
Dzinjalamala Fraction K
Nyirenda Osward M
Thesing Phillip C
Jacob Christopher G
Molyneux Malcolm E
Taylor Terrie E
Plowe Christopher V
Laufer Miriam K
spellingShingle Shaukat Ayesha M
Gilliams Elizabeth A
Kenefic Leo J
Laurens Matthew B
Dzinjalamala Fraction K
Nyirenda Osward M
Thesing Phillip C
Jacob Christopher G
Molyneux Malcolm E
Taylor Terrie E
Plowe Christopher V
Laufer Miriam K
Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment
Malaria Journal
Malaria
Sulphadoxine-pyrimethamine
Drug efficacy
Genotyping
Recrudescent infections
New infections
Malawi
Anaemia
author_facet Shaukat Ayesha M
Gilliams Elizabeth A
Kenefic Leo J
Laurens Matthew B
Dzinjalamala Fraction K
Nyirenda Osward M
Thesing Phillip C
Jacob Christopher G
Molyneux Malcolm E
Taylor Terrie E
Plowe Christopher V
Laufer Miriam K
author_sort Shaukat Ayesha M
title Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment
title_short Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment
title_full Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment
title_fullStr Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment
title_full_unstemmed Clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment
title_sort clinical manifestations of new <it>versus</it> recrudescent malaria infections following anti-malarial drug treatment
publisher BMC
series Malaria Journal
issn 1475-2875
publishDate 2012-06-01
description <p>Abstract</p> <p>Background</p> <p>Distinguishing new from recrudescent infections in post-treatment episodes of malaria is standard in anti-malarial drug efficacy trials. New infections are not considered malaria treatment failures and as a result, the prevention of subsequent episodes of malaria infection is not reported as a study outcome. However, in moderate and high transmission settings, new infections are common and the ability of a short-acting medication to cure an initial infection may be outweighed by its inability to prevent the next imminent infection. The clinical benefit of preventing new infections has never been compared to that of curing the initial infection.</p> <p>Methods</p> <p>Children enrolled in a sulphadoxine-pyrimethamine efficacy study in Blantyre, Malawi from 1998–2004 were prospectively evaluated. Six neutral microsatellites were used to classify new and recrudescent infections in children aged less than 10 years with recurrent malaria infections. Children from the study who did not experience recurrent parasitaemia comprised the baseline group. The odds of fever and anaemia, the rate of haemoglobin recovery and time to recurrence were compared among the groups.</p> <p>Results</p> <p>Fever and anemia were more common among children with parasitaemia compared to those who remained infection-free throughout the study period. When comparing recrudescent vs. new infections, the incidence of fever was not statistically different. However, children with recrudescent infections had a less robust haematological recovery and also experienced recurrence sooner than those whose infection was classified as new.</p> <p>Conclusions</p> <p>The results of this study confirm the paramount importance of providing curative treatment for all malaria infections. Although new and recrudescent infections caused febrile illnesses at a similar rate, recurrence due to recrudescent infection did have a worsened haemological outcome than recurrence due to new infections. Local decision-makers should take into account the results of genotyping to distinguish new from recrudescent infections when determining treatment policy on a population level. It is appropriate to weigh recrudescent malaria more heavily than new infection in assessing treatment efficacy.</p>
topic Malaria
Sulphadoxine-pyrimethamine
Drug efficacy
Genotyping
Recrudescent infections
New infections
Malawi
Anaemia
url http://www.malariajournal.com/content/11/1/207
work_keys_str_mv AT shaukatayesham clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment
AT gilliamselizabetha clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment
AT keneficleoj clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment
AT laurensmatthewb clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment
AT dzinjalamalafractionk clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment
AT nyirendaoswardm clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment
AT thesingphillipc clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment
AT jacobchristopherg clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment
AT molyneuxmalcolme clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment
AT taylorterriee clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment
AT plowechristopherv clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment
AT laufermiriamk clinicalmanifestationsofnewitversusitrecrudescentmalariainfectionsfollowingantimalarialdrugtreatment
_version_ 1725824015150350336